Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Vorapaxar sulfate, Zontivity
vorapaxar · 6 trials · 9 indications
Vacuolization is defined as the presence of more than one vacuole (defined as a clear, round structure in the INL of the retina of at least 30 microns in diameter) compared to baseline in either the left or right eye as evaluated by ocular coherence tomography (OCT).
The time (in days) from study start to the first occurrence of any of the following clinical outcomes was recorded: CV death, MI, stroke, or UCR. A Clinical Endpoints Committee (CEC) reviewed and adjudicated each suspected efficacy endpoint event while blinded to treatment. Participants who did not have any endpoint event until last visit or participants who were lost to follow-up and had no event were censored at the time of last available information (last study visit). If a participant had a fatal event that was not part of a specific endpoint for analysis, they were censored at the time of death. The Kaplan-Meier estimate reports the percentage of participants who experienced CV death, MI, stroke, or UCR within 3 years from randomization.
Time to AV fistula functional maturation (defined as successful cannulation of the AV fistula for six hemodialysis sessions within three weeks).
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug.
An adverse event (AE) is any unfavorable and unintended change in the structure, function, or chemistry of the body temporarily associated with study drug administration, whether or not considered related to study drug. MACE events were defined as nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization. All MACE events were excluded from this analysis.
Mean of week 8 and week 12 minus week 0 (on log10 scale) then back transforming the log10 difference to obtain percentage change from baseline.
| Arm | Type | Description |
|---|---|---|
| Vorapaxar | EXPERIMENTAL | Participants receive a vorapaxar 2.5 mg tablet administered orally once daily for 1 year |
| Placebo | PLACEBO_COMPARATOR | Participants receive a matching placebo tablet to vorapaxar administered orally once daily for 1 year |
| Vorapaxar intervention | ACTIVE_COMPARATOR | This arm will receive the study drug: Vorapaxar sulfate. The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm). |
| Placebo intervention | PLACEBO_COMPARATOR | This arm will receive the matching placebo. The investigators expect to enroll 128 patients. Patients will be assigned to treatment groups with a 1:1 randomization in blocks of 4 at the conclusion of the AV fistula creation. Patients will be stratified based on fistula location (lower arm versus upper arm). |
| Vorapaxar 20 mg/1 mg | EXPERIMENTAL | Vorapaxar 20 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine) |
| Vorapaxar 20 mg/2.5 mg | EXPERIMENTAL | Vorapaxar 20 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine) |
| Vorapaxar 40 mg/1 mg | EXPERIMENTAL | Vorapaxar 40 mg loading dose + daily 1 mg maintenance dose + standard of care (Aspirin + Ticlopidine) |
| Vorapaxar 40 mg/2.5 mg | EXPERIMENTAL | Vorapaxar 40 mg loading dose + daily 2.5 mg maintenance dose + standard of care (Aspirin + Ticlopidine) |
| Vorapaxar 2.5 mg + Aspirin | EXPERIMENTAL | Vorapaxar oral tablets; once daily for 60 days + Aspirin. |
| Vorapaxar 1 mg + Aspirin | EXPERIMENTAL | Vorapaxar oral tablets; once daily for 60 days + Aspirin. |
| Placebo + Aspirin | PLACEBO_COMPARATOR | Placebo oral tablets; once daily for 60 days + Aspirin |
| Name | Type | Description |
|---|---|---|
| Vorapaxar 2.5 mg | DRUG | Vorapaxar 2.5 mg oral tablet |
| Placebo | DRUG | matching placebo oral tablet |
| Vorapaxar | DRUG | 2.5-mg tablet daily for at least 1 year |
| Vorapaxar sulfate | DRUG | The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery. |
| Aspirin | DRUG | Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days. |
| Clopidogrel | DRUG | 100 mg two or three times daily for 60 days. |
| Vorapaxar 1 mg | DRUG | Oral tablets; once daily for 60 days |
| Aspirin 75-150 mg | DRUG | oral tablets; once daily for 60 days |
Inclusion Criteria: * Evidence or a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems Exclusion Criteria: * The study will include participants who meet none of the exclusion criteria for the parent protocol (P04737) and also the following: * history o...
Top 10 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 7 | PHASE3 | Ziltivekimab, Zenagamtide |
| Eli Lilly and Company | LLY | 6 | PHASE3 | Lepodisiran, Retatrutide, Muvalaplin, Orforglipron, Clazakizumab |
| Novartis AG Sponsored ADR | NVS | 8 | PHASE3 | Inclisiran, Pelacarsen |
| Amgen Inc. | AMGN | 4 | PHASE3 | Olpasiran, Maridebart cafraglutide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide |
| NewAmsterdam Pharma Company N.V. | NAMS | 2 | PHASE3 | Obicetrapib |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Genentech, Inc. | RHHBY | 1 | PHASE2 | Selnoflast |
| Verve Therapeutics, Inc. | VERV | 2 | PHASE2 | VERVE-102 |
Vorapaxar is a small molecule drug developed by Merck & Company, Inc. (MRK). It is an antagonist of F2R, also known as the protease-activated receptor 1 (PAR-1). It has been studied in clinical trials for conditions including AV fistula maturation, atherosclerosis, cerebral infarction, and HIV. It is also known as vorapaxar 2.5 mg and vorapaxar sulfate.
Vorapaxar targets F2R, the protease-activated receptor 1 (PAR-1), and acts as an antagonist. By blocking this receptor, vorapaxar inhibits thrombin-mediated platelet activation. This mechanism distinguishes it from other antiplatelet agents that work through different pathways.
Vorapaxar is developed by Merck & Company, Inc., which trades under the ticker MRK. Merck has sponsored clinical trials of vorapaxar across multiple indications, including AV fistula maturation, HIV, cerebral infarction, and atherosclerosis.
Vorapaxar has been studied in Phase 1 and Phase 2 clinical trials. It is an investigational drug and is not approved by the FDA for the indications studied. All three completed trials have finished, and there are currently no active trials of vorapaxar.
Vorapaxar has been evaluated in completed trials including NCT02475837 for AV fistula maturation in hemodialysis access, NCT02394730 for HIV-related inflammatory and coagulation endpoints, NCT00684515 in Japanese subjects with cerebral infarction, and NCT00684203 in Japanese subjects with acute coronary syndrome. All trials are completed.
Yes, vorapaxar sulfate and vorapaxar 2.5 mg are alternative names for vorapaxar. Vorapaxar sulfate refers to the sulfate salt form of the drug, while vorapaxar 2.5 mg refers to a specific dosage strength. All refer to the same active pharmaceutical ingredient developed by Merck.